A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms RAINFALL
Sponsors Eli Lilly and Company; Eli Lilly Japan

Most Recent Events

01 Dec 2020 This trial has been completed in Netherlands, according to European Clinical Trials Database.
17 Nov 2020 Status changed from active, no longer recruiting to completed.
14 Nov 2020 This trial has been completed in Hungary and Belgium (Global End Date: 14 Aug 2020), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight